209 related articles for article (PubMed ID: 18441313)
1. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways.
Klettner A; Roider J
Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4523-7. PubMed ID: 18441313
[TBL] [Abstract][Full Text] [Related]
2. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells.
Spitzer MS; Yoeruek E; Sierra A; Wallenfels-Thilo B; Schraermeyer U; Spitzer B; Bartz-Schmidt KU; Szurman P
Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1837-42. PubMed ID: 17347807
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.
Klettner A; Recber M; Roider J
Graefes Arch Clin Exp Ophthalmol; 2014 Oct; 252(10):1593-8. PubMed ID: 25047874
[TBL] [Abstract][Full Text] [Related]
4. Toxicity testing of the VEGF inhibitors bevacizumab, ranibizumab and pegaptanib in rats both with and without prior retinal ganglion cell damage.
Thaler S; Fiedorowicz M; Choragiewicz TJ; Bolz S; Tura A; Henke-Fahle S; Yoeruek E; Zrenner E; Bartz-Schmidt KU; Ziemssen F; Schuettauf F
Acta Ophthalmol; 2010 Aug; 88(5):e170-6. PubMed ID: 20491691
[TBL] [Abstract][Full Text] [Related]
5. Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells.
Klettner AK; Kruse ML; Meyer T; Wesch D; Kabelitz D; Roider J
Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1601-8. PubMed ID: 19597740
[TBL] [Abstract][Full Text] [Related]
6. Comparison of choroidal and retinal endothelial cells: characteristics and response to VEGF isoforms and anti-VEGF treatments.
Stewart EA; Samaranayake GJ; Browning AC; Hopkinson A; Amoaku WM
Exp Eye Res; 2011 Nov; 93(5):761-6. PubMed ID: 21970900
[TBL] [Abstract][Full Text] [Related]
7. [VEGF in age-related macular degeneration. Part II. VEGF inhibitors use in age-related macular degeneration treatment].
Wylegała E; Teper SJ
Klin Oczna; 2007; 109(1-3):97-100. PubMed ID: 17687925
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
Schottler J; Randoll N; Lucius R; Caliebe A; Roider J; Klettner A
Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells.
Spitzer MS; Wallenfels-Thilo B; Sierra A; Yoeruek E; Peters S; Henke-Fahle S; Bartz-Schmidt KU; Szurman P;
Br J Ophthalmol; 2006 Oct; 90(10):1316-21. PubMed ID: 16723358
[TBL] [Abstract][Full Text] [Related]
10. VEGF antagonists decrease barrier function of retinal pigment epithelium in vitro: possible participation of intracellular glutathione.
Miura Y; Klettner A; Roider J
Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4848-55. PubMed ID: 20435596
[TBL] [Abstract][Full Text] [Related]
11. Vascular Endothelial Growth Factor (VEGF) Concentration Is Underestimated by Enzyme-Linked Immunosorbent Assay in the Presence of Anti-VEGF Drugs.
Takahashi H; Nomura Y; Nishida J; Fujino Y; Yanagi Y; Kawashima H
Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):462-6. PubMed ID: 26868748
[TBL] [Abstract][Full Text] [Related]
12. Retinal function and morphology in rabbit after intravitreal injection of VEGF inhibitors.
Myers AC; Lövestam Adrian M; Bruun A; Ghosh F; Andréasson S; Ponjavic V
Curr Eye Res; 2012 May; 37(5):399-407. PubMed ID: 22510009
[TBL] [Abstract][Full Text] [Related]
13. Influence of non-toxic doses of bevacizumab and ranibizumab on endothelial functions and inhibition of angiogenesis.
Barzelay A; Lowenstein A; George J; Barak A
Curr Eye Res; 2010 Sep; 35(9):835-41. PubMed ID: 20795866
[TBL] [Abstract][Full Text] [Related]
14. Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway.
Giurdanella G; Anfuso CD; Olivieri M; Lupo G; Caporarello N; Eandi CM; Drago F; Bucolo C; Salomone S
Biochem Pharmacol; 2015 Aug; 96(3):278-87. PubMed ID: 26056075
[TBL] [Abstract][Full Text] [Related]
15. Penetration of bevacizumab and ranibizumab through retinal pigment epithelial layer in vitro.
Terasaki H; Sakamoto T; Shirasawa M; Yoshihara N; Otsuka H; Sonoda S; Hisatomi T; Ishibashi T
Retina; 2015 May; 35(5):1007-15. PubMed ID: 25627091
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells.
Carneiro A; Falcão M; Pirraco A; Milheiro-Oliveira P; Falcão-Reis F; Soares R
Exp Eye Res; 2009 Mar; 88(3):522-7. PubMed ID: 19135441
[TBL] [Abstract][Full Text] [Related]
17. Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab.
Meyer CH; Holz FG
Eye (Lond); 2011 Jun; 25(6):661-72. PubMed ID: 21455242
[TBL] [Abstract][Full Text] [Related]
18. Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage.
Klettner A; Grotelüschen S; Treumer F; Roider J; Hillenkamp J
Br J Ophthalmol; 2015 Jun; 99(6):864-9. PubMed ID: 25740806
[TBL] [Abstract][Full Text] [Related]
19. Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences.
Deissler HL; Deissler H; Lang GE
Br J Ophthalmol; 2012 Jul; 96(7):1023-8. PubMed ID: 22539748
[TBL] [Abstract][Full Text] [Related]
20. Effects of bevacizumab (Avastin) on retinal cells in organotypic culture.
Kaempf S; Johnen S; Salz AK; Weinberger A; Walter P; Thumann G
Invest Ophthalmol Vis Sci; 2008 Jul; 49(7):3164-71. PubMed ID: 18344448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
